This program aims to help clinicians better identify clinical presentation features of atopic dermatitis (AD) warranting a timely and accurate differential diagnosis; recognize patients for whom biologic therapies should be considered as part of treatment plans for the management of moderate-to-severe AD, and coordinate with specialists to provide patient-specific, long-term care for moderate-to-severe AD.

RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026

This innovative online enduring activity is designed to enhance clinicians’ understanding and management of atopic dermatitis (AD). It equips healthcare professionals with the knowledge to recognize the clinical characteristics of AD, highlighting key differences between adults and pediatric presentations. The program also explores the therapeutic benefits of biologics for patients with moderate-to-severe AD. Additionally, it promotes a multidisciplinary team (MDT) approach to improve collaboration across specialties, emphasizing timely dermatology referrals for optimal patient care.

RELEASED DATE: September 30, 2025
EXPIRATION DATE: September 30, 2026

• Develop treatment regimens that address the immunological and neural components of prurigo nodularis (PN)
• Integrate patient-specific factors, such as quality of life and comorbidities, into the selection of treatment options for the management of PN
• Assess clinical trial data on the efficacy and safety of emerging therapies for the treatment of PN